April 29, 2014—Because refluxing perforators contribute to venous ulceration, investigators sought to describe patient characteristics and procedural factors that impact both rates of incompetent perforator vein (IPV) thrombosis with ultrasound-guided sclerotherapy (UGS) and the healing of venous ulcers (CEAP 6) without axial reflux. The study’s findings were published by Misaki M. Kiguchi, MD, et al in the Journal of Vascular Surgery (2014;59:1368–1379).
April 7, 2014—Boehringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, CT) announced that the US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of venous thromboembolism (VTE), including both deep venous thrombosis (DVT) and pulmonary embolism (PE), in patients who have been treated with a parenteral anticoagulant for 5 to 10 days and to reduce the risk of recurrent DVT and PE. Pradaxa is also approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation.
Venous expert Jose I. Almeida, MD, discusses the high mark set by current thermal ablation data, the forces affecting adoption of new therapies, and the economic realities facing today’s venous practices.
A look at the new generation of thermal tumescent and nonthermal nontumescent technologies and their best applications.
How we got here, where we are now, and goals for the future.
On 29 April 2014, TriVascular Technologies announced FDA-approved changes to the indication statement for the Ovation and Ovation Prime Abdominal Stent Graft Systems (Ovation system).
Benjamin Starnes (Seattle, USA) told the audience attending yesterday’s mini symposium on acute aortic transection that intravascular ultrasound (IVUS) was an important tool in the management of patients with blunt aortic injury undergoing thoracic endovascular aortic repair (TEVAR) because it helps to ensure accurate sizing of the endograft and prevent rupture. The session also reviewed the differences between image-based classifications of blunt aortic injury.
The CX Great Debate saw Peter Taylor, London, UK, and Richard Gibbs, Imperial College, London, UK, persuaded 71% of the audience at the Charing Cross International Symposium yesterday to vote for their position against the motion “For uncomplicated type B dissections, early intervention is indicated”.
Michael Dake, Stanford, USA, outlined the first experiences with the Gore TAG (W L Gore) thoracic branch endoprosthesis and Frank R Arko, Charlotte, USA, presented on the MONA LSA (Medtronic) branched device results at a session yesterday. Both speakers shared early cases and their results.
At the ilegx Collaboration Day, attendees learnt about the best management therapies for diabetic foot care and vascular reconstruction in critical limb ischaemia patients and for the second year running, the symposium broadcast edited live cases treating superficial femoral artery lesions to the Far East and North America in an event named Endovascular Electronic Education, sponsored by Abbott Vascular.
Giovanni Pratesi (Florence, Italy) reported that the two-year results of the INNOVATION study (A multicentre, open-label, prospective, non-randomised study of the Cordis Incraft system in subjects with abdominal aortic aneurysms) confirm the “very promising results” of the one-year outcomes of the Incraft bifurcated stent graft system (Cordis). The results, presented at the Charing Cross Symposium 2014 (5-8 April, London, UK), showed that the system was not associated with any endoleaks at two years in patients undergoing endovascular aortic aneurysm repair (EVAR).
Attendees at the CX Innovation Showcase learnt about the latest branched devices for endovascular aneurysm repair yesterday. New technologies for the vascular and endovascular treatment of lower limb, venous and carotid disease and arteriovenous access were also discussed. Stephen Greenhalgh (London, UK) and Andrew Holden (Auckland, New Zealand) were the chairmen of the session.
The first-ever presentation of 12-month data from the randomised multicentre IN.PACT SFA trial revealed that treatment with the IN.PACT Admiral drug-eluting balloon (Medtronic) was significantly superior to percutaneous transluminal angioplasty in terms of reinterventions and patency. The results were presented at the Charing Cross Symposium 2014 (5–8 April 2014, London, UK).
Andrew Holden, Auckland, New Zealand, presented data for on the developments in bioresorbable technology yesterday. He said that, as drug-eluting balloon data are limited to short and intermediate length lesions, bioresorbable stents or scaffolds are an “exciting prospect” for the future.
Andrew Bradbury (Birmingham, UK) reported that a new randomised controlled trial, BASIL 2, has been launched because there is an “urgent need” to undertake pragmatic, scientifically robust and publically-funded randomised controlled trials of endovascular interventions in patients with severe limb ischaemia.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos